<DOC>
	<DOCNO>NCT02730871</DOCNO>
	<brief_summary>The purpose study evaluate additive intraocular pressure ( IOP ) lower effect Brinzolamide 1 % /Brimonidine 0.2 % ( SIMBRINZA® ) dose twice daily ( BID ) add Travoprost 0.004 % /Timolol 0.5 % ( DUOTRAV® ) subject open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Safety Efficacy SIMBRINZA® BID Adjunctive DUOTRAV®</brief_title>
	<detailed_description>This study divide 2 sequential phase total 5 visit . Phase I study open-labeled Screening/Eligibility Phase , include Screening Visit follow 2 Eligibility Visits . Phase II study randomize , double-masked Treatment Phase , include 2 on-therapy visit : Visit 4 ( Week 2 ) Visit 5 ( Week 6 , Exit Visit ) .</detailed_description>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>Diagnosis openangle glaucoma ( include pseudoexfoliation pigment dispersion glaucoma ) ocular hypertension . Currently treatment Travoprost 0.004 % /Timolol 0.5 % prescribe approved country , even dose least 28 day prior screen , opinion Investigator may benefit IOP lower . Mean IOP measurement Eligibility 1 Eligibility 2 visit , least 1 eye ( eye ( ) ≥ 21 ≤ 28 mmHg 9:00 Travoprost 0.004 % / Timolol 0.5 % solution . Able understand sign inform consent form approve Institutional Review Board/Ethics Committee . Willing able attend study visit . Other protocoldefined inclusion criterion may apply . Women childbearing potential : postmenopausal least 1 year less 6 week since sterilization , currently pregnant ; positive result urine pregnancy test Screening ; intend become pregnant study period ; breastfeeding ; agreement use adequate birth control method prevent pregnancy throughout study . Any form glaucoma openangle glaucoma ocular hypertension . Severe central visual field loss either eye . Chronic , recurrent severe inflammatory eye disease either eye . Ocular trauma either eye within past 6 month prior Screening visit . Ocular infection ocular inflammation either eye within past 3 month prior Screening visit . Retinal degeneration , diabetic retinopathy , retinal detachment either eye . Bestcorrected visual acuity score worse 55 ETDRS letter ( equivalent approximately 20/80 Snellen , 0.60 logMAR 0.25 decimal ) either eye . Other ocular pathology ( include severe dry eye ) either eye may , opinion Investigator , preclude safe administration study medication . Intraocular surgery either eye within past 6 month prior Screening visit . Ocular laser surgery either eye within past 3 month prior Screening visit . Any condition include severe illness would make subject , opinion Investigator , unsuitable study . Asthma , history asthma , severe chronic obstructive pulmonary disease . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>